| Literature DB >> 35447064 |
Aaron C Miller, Alan T Arakkal, Daniel K Sewell, Alberto M Segre, Sriram V Pemmaraju, Philip M Polgreen.
Abstract
We evaluated whether hospitalized patients without diagnosed Clostridioides difficile infection (CDI) increased the risk for CDI among their family members after discharge. We used 2001-2017 US insurance claims data to compare monthly CDI incidence between persons in households with and without a family member hospitalized in the previous 60 days. CDI incidence among insurance enrollees exposed to a recently hospitalized family member was 73% greater than enrollees not exposed, and incidence increased with length of hospitalization among family members. We identified a dose-response relationship between total days of within-household hospitalization and CDI incidence rate ratio. Compared with persons whose family members were hospitalized <1 day, the incidence rate ratio increased from 1.30 (95% CI 1.19-1.41) for 1-3 days of hospitalization to 2.45 (95% CI 1.66-3.60) for >30 days of hospitalization. Asymptomatic C. difficile carriers discharged from hospitals could be a major source of community-associated CDI cases.Entities:
Keywords: Bacteria; C. difficile; Clostridioides difficile; United States; antimicrobial resistance; asymptomatic infections; enteric infections; family transmission; hospitalization; patient discharge; risk factors
Mesh:
Year: 2022 PMID: 35447064 PMCID: PMC9045444 DOI: 10.3201/eid2805.212023
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Baseline enrollment characteristics of families with multiple infected members using a 60-day exposure window in study of asymptomatic Clostridioides difficile transmission among household members, United States*
| Characteristics | All enrollees. no. (%) | No. (%) episodes of index CDI diagnosis† | No. (%) cases of possible transmission after family member hospitalization |
| No. CDI cases | NA | 224,818 | 6,575 |
| No. enrollees | 142,125,247 (100) | 194,424 (100) | 6,453 (100) |
| Age group at enrollment or CDI diagnosis, y | |||
| 0–17 | 47,733,847 (33.6) | 19,719 (8.8) | 547 (8.3) |
| 18–40 | 46,634,859 (32.8) | 37,259 (16.6) | 1,156 (17.6) |
| 41–65 | 44,039,682 (31.0) | 103,430 (46.0) | 1,822 (27.7) |
| >65 | 3,716,859 (2.6) | 64,410 (28.6) | 3,050 (46.4) |
| Sex | |||
| M | 70,485,475 (49.6) | 99,133 (44.1) | 2,798 (42.6) |
| F | 71,639,772 (50.4) | 125,685 (55.9) | 3,777 (57.4) |
| Family size | |||
| 2 | 36,598,138 (25.8) | 134,644 (59.9) | 4,166 (63.4) |
| 3 | 29,857,746 (21.0) | 36,236 (16.1) | 905 (13.8) |
| 4 | 40,705,784 (28.6) | 34,559 (15.4) | 839 (12.8) |
| 5 | 21,536,725 (15.2) | 13,517 (6.0) | 409 (6.2) |
| >5 | 13,426,854 (9.4) | 5,862 (2.6) | 256 (3.9) |
*CDI, Clostridioides difficile infection; NA, not applicable. †Events occurring >60 days before another episode.
Bivariate comparisons of unadjusted incidence rates and incidence rate ratios for infection incidence across various patient strata using a 60-day exposure window in study of asymptomatic Clostridioides difficile transmission among household members, United States*
| Variable | Exposed to previously hospitalized family member | Not exposed to previously hospitalized family member | Unadjusted IRR | ||||||
| CDI cases | Total enrollee months | CDI incidence† |
| CDI cases | Total enrollee months | CDI incidence† | |||
| Overall | 3,871 | 69,675,026 | 5.56 |
| 160,779 | 4,998,101,178 | 3.22 | 1.73 | |
| Age group, y | |||||||||
| 0–17 | 317 | 24,432,280 | 1.30 | 15,615 | 1,445,786,086 | 1.08 | 1.20 | ||
| 18–40 | 567 | 19,978,891 | 2.84 | 29,718 | 1,427,785,479 | 2.08 | 1.37 | ||
| 41–65 | 1,193 | 19,281,059 | 6.19 | 74,803 | 1,868,106,655 | 4.00 | 1.55 | ||
| >65 | 1,794 | 5,982,798 | 29.99 |
| 40,643 | 256,422,958 | 15.85 | 1.89 | |
| Sex | |||||||||
| M | 1,698 | 37,945,564 | 4.47 | 67,378 | 2,488,714,427 | 2.71 | 1.65 | ||
| F | 2,173 | 31,729,463 | 6.85 |
| 93,401 | 2,509,386,752 | 3.72 | 1.84 | |
| Outpatient antimicrobial drug use within 60 days | |||||||||
| None | 2,419 | 63,230,032 | 3.83 | 100,792 | 4,575,861,567 | 2.20 | 1.74 | ||
| Low-risk drugs | 292 | 2,979,748 | 9.80 | 11,944 | 201,200,918 | 5.94 | 1.65 | ||
| High-risk drugs | 1,160 | 3,465,248 | 33.48 |
| 48,043 | 221,038,693 | 21.74 | 1.54 | |
| PPI use within 30 days | |||||||||
| N | 3,477 | 68,273,806 | 5.09 | 146,185 | 4,913,346,960 | 2.98 | 1.71 | ||
| Y | 394 | 1,401,221 | 28.12 |
| 14,594 | 84,754,218 | 17.22 | 1.63 | |
| Infant age <2 y in family | |||||||||
| N | 3,489 | 48,618,765 | 7.18 | 151,291 | 4,597,497,625 | 3.29 | 2.18 | ||
| Y | 382 | 21,056,262 | 1.81 | 9,488 | 400,603,553 | 2.37 | 0.76 | ||
*IRRs compare CDI incidence among persons exposed to a family member previously hospitalized for >1 d relative incidence for to those not exposed to a previously hospitalized family member. The overall incidence rate ratio among those exposed to a previously hospitalized family member relative to those unexposed was 1.73 and was >1 across all strata. CDI, Clostridioides difficile infection; IRR, incidence rate ratio; PPI, proton-pump inhibitor. †Cases per 100,000 enrollee months.
Number of cases and enrollee-months in each exposure bin for total days of household-hospitalization using a 60-day exposure window in study of asymptomatic Clostridioides difficile transmission among household members, United States*
| No. days family members spent hospitalized | 60-day exposure window | ||
|---|---|---|---|
| No. CDI cases | Total enrollment months | Incidence† | |
| 0 | 160,267 | 4,980,648,694 | 3.22 |
| 1–3 | 2,336 | 52,798,719 | 4.42 |
| 4–10 | 1,519 | 27,457,461 | 5.53 |
| 11–20 | 315 | 4,338,929 | 7.26 |
| 21–30 | 107 | 1,317,610 | 8.12 |
| >30 | 106 | 1,214,792 | 8.73 |
*CDI, Clostridioides difficile infection. †Cases per 100,000 enrollment months.
Results of regression analysis of incidence rate ratio for Clostridioides difficile infection using quasi-Poisson model and 60-day exposure window in study of asymptomatic C. difficile transmission among household members, United States*
| Variable | IRR (95% CI) |
|---|---|
| No. days member was hospitalized within 60 d | |
| 0 | Referent |
| 1–3 | 1.30 (1.19–1.41) |
| 4–10 | 1.46 (1.32–1.62) |
| 11–20 | 1.79 (1.43–2.23) |
| 21–30 | 2.17 (1.48–3.18) |
| >30 | 2.45 (1.66–3.60) |
| Age group, y | |
| 0–17 | Referent |
| 18–40 | 1.71 (1.65–1.78) |
| 41–65 | 2.97 (2.86–3.08) |
| >65 | 9.32 (8.92–9.73) |
| Sex | |
| M | Referent |
| F | 1.30 (1.28–1.33) |
| Outpatient antimicrobial drug use within 60 d | |
| None | Referent |
| Low-risk drugs | 2.69 (2.59–2.79) |
| High-risk drugs | 8.83 (8.63–9.03) |
| PPI use within 30 d | 2.23 (2.15–2.30) |
| Infant <2 y in family | 1.51 (1.44–1.58) |
*Models were adjusted for year, month, and family size. Regression models included an offset for number of enrollment months. Because family hospitalization exposure group was followed for 60 days to identify secondary Clostridioides difficile infection, the length of their enrollment period is 60 days. For the unexposed group, the length of enrollment was the length of a given month. IRR, incident rate ratio; PPI, proton-pump inhibitor.